PerserisTM: A New and Long-Acting, Atypical Antipsychotic Drug-Delivery System.

Perseris: A new, long-acting, atypical antipsychotic drug-delivery system.

[1]  S. Leucht,et al.  Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method , 2017, Schizophrenia Research.

[2]  V. Ivaturi,et al.  Exposure‐response analysis after subcutaneous administration of RBP‐7000, a once‐a‐month long‐acting Atrigel formulation of risperidone , 2017, British journal of clinical pharmacology.

[3]  Zvi Weiss,et al.  Long-Acting Injectable Antipsychotics for Schizophrenia: Sociodemographic Characteristics and Treatment Adherence. , 2017, The Primary Care Companion For CNS Disorders.

[4]  M. Fava,et al.  Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study , 2016, Schizophrenia Research.

[5]  C. Parker,et al.  A review of the efficacy and tolerability of antipsychotic long‐acting injections , 2016 .

[6]  M. Fava,et al.  Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study , 2016, Journal of clinical psychopharmacology.

[7]  J. Stoddard,et al.  Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. , 2015, Journal of managed care & specialty pharmacy.

[8]  Yanning Liu,et al.  Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial. , 2015, JAMA psychiatry.

[9]  J. Lindenmayer,et al.  Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. , 2015, The Journal of clinical psychiatry.

[10]  P. Fudala,et al.  Population pharmacokinetic modeling and simulation to guide dose selection for RBP‐7000, a new sustained‐release formulation of risperidone , 2015, Journal of clinical pharmacology.

[11]  P. Fudala,et al.  Population Pharmacokinetics and Prediction of Dopamine D2 Receptor Occupancy After Multiple Doses of RBP‐7000, a New Sustained‐Release Formulation of Risperidone, in Schizophrenia Patients on Stable Oral Risperidone Treatment , 2014, Clinical Pharmacokinetics.

[12]  J. Casoy,et al.  Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia , 2013, Patient preference and adherence.

[13]  P. Fudala,et al.  A model‐based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP‐7000, a new, long‐acting, sustained‐released formulation of risperidone , 2013, Journal of clinical pharmacology.

[14]  J. Fastenau,et al.  Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis , 2013, BMC Psychiatry.

[15]  P. McCrone,et al.  The Cost Effectiveness of Long-Acting/Extended-Release Antipsychotics for the Treatment of Schizophrenia , 2013, Applied Health Economics and Health Policy.

[16]  S. Candrilli,et al.  Health Care Utilization and Costs among Medicaid-enrolled Patients with Schizophrenia Experiencing Multiple Psychiatric Relapses , 2012 .

[17]  Annette Lee,et al.  Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. , 2012, Archives of general psychiatry.

[18]  M. Stensland,et al.  An examination of costs, charges, and payments for inpatient psychiatric treatment in community hospitals. , 2012, Psychiatric services.

[19]  J. Kane,et al.  Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. , 2012, The Journal of clinical psychiatry.

[20]  T. Boaz,et al.  Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population. , 2011, Journal of Clinical Psychiatry.

[21]  J. Tiihonen,et al.  A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. , 2011, The American journal of psychiatry.

[22]  R. Conley,et al.  The cost of relapse and the predictors of relapse in the treatment of schizophrenia , 2010, BMC psychiatry.

[23]  W. Fleischhacker,et al.  Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. , 2005, The British journal of psychiatry : the journal of mental science.

[24]  H. Nasrallah,et al.  Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. , 2004, The Journal of clinical psychiatry.

[25]  Christian R. Dolder,et al.  Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. , 2002, The Journal of clinical psychiatry.

[26]  R. Diamond,et al.  Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA , 2012, PharmacoEconomics.

[27]  I. Singh,et al.  Atrigel: A potential parenteral controlled drug delivery system , 2010 .

[28]  A. Vermeulen,et al.  Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia , 2009, Clinical pharmacokinetics.

[29]  S. Thompson,et al.  Risperdal Consta TM : The First Long-Acting Atypical Antipsychotic Agent , 2004 .